Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS.

Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 2018 02 13; 90(7):e565-e574.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.